Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Nov. 27 Company Quick Takes: Orexo, GAIA in second deal for substance abuse digital therapy; plus PDUFA date for Verrica's skin infection candidate and $25M fol

November 27, 2019 8:12 PM UTC
Updated on Nov 27, 2019 at 9:06 PM UTC

Orexo gets U.S. rights to GAIA's alcohol abuse digital therapeutic
Orexo AB (SSE:ORX) licensed exclusive U.S. rights from GAIA AG to vorvida, a digital therapeutic to treat alcohol use disorder; financial terms are undisclosed. Orexo will be responsible for FDA approval and commercialization of vorvida. The deal follows an August partnership between the two companies to develop a psychosocial support product intended to enhance the use of Orexo's Zubsolv buprenorphine/naloxone to treat opioid use disorder (see "Orexo, GAIA to Develop Digital Therapeutic for Opioid Use Disorder").

Verrica's VP-102 under FDA review
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) said FDA accepted for review an NDA for VP-102 to treat the viral skin infection molluscum contagiosum, for which there are no FDA-approved therapies. The topical formulation of cantharidin has a PDUFA date of July 13...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article